Objective: To test the hypothesis that statins improve hyperandrogenemia in women with polycystic ovary syndrome (PCOS).Design: Prospective, randomized trial.Setting: Academic medical center.Patient(s): Forty- eight w...Objective: To test the hypothesis that statins improve hyperandrogenemia in women with polycystic ovary syndrome (PCOS).Design: Prospective, randomized trial.Setting: Academic medical center.Patient(s): Forty- eight women with PCOS.Intervention(s): Subjects were randomized to a statin group (simvastatin, 20 mg daily plus oral contraceptive pill [OCP]; n = 24) or an OCP group (OCP alone; n = 24).Main Outcome Measure(s): Serum T.Result(s): Baseline parameters of both groups were comparable.After 12 weeks of treatment, serum T levels declined by 41% in the statin group and by 14% in the OCP group.In the statin group, there was a greater decrease of LH (43% decrease vs.9% in the OCP group) and a greater decline of LH/FSH ratio (44% vs.12% ).In the statin group, total cholesterol declined by 10% and low- density lipoprotein (LDL) by 24% .In the OCP group, total cholesterol increased by 8% , and LDL was unchanged.Conclusion(s): This is the first study demonstrating that statin decreases T levels and normalizes gonadotropin levels in women with PCOS.Statin therapy might offer a novel approach, providing endocrine and cardiovascular benefits.展开更多
Objective: Patients with polycystic ovary syndrome frequently suffer from hyperinsulinemia and adverse lipid profile. This study evaluated effects of metformin on lipid profile. Study design: Lipid profiles in hyperin...Objective: Patients with polycystic ovary syndrome frequently suffer from hyperinsulinemia and adverse lipid profile. This study evaluated effects of metformin on lipid profile. Study design: Lipid profiles in hyperinsulinemic (n = 43) and normoinsulinemic (n = 45) subjects were compared. Hyperinsulinemic subjects were treated with metformin (500 mg po tid) and lipid profiles were reevaluated at 3 and 6 months of treatment. Results: The hyperinsulinemic group had significantly lower high-density lipoprotein (HDL) (by 11% ), higher total cholesterol to HDL ratio (by 23% ), and greater trigly cerides(by 57% ) than the normoinsulinemic group. Six- month metformin therapy in hyperinsulinemic women was associated with a significant decrease of insulin level (by 35% ), total cholesterol(by 11% ), low-density lipoprotein (LDL) (by 12% ), and triglycerides (by 33% ). Levels of lipids in hyperinsulinemic women after metformin therapy were comparable to levels observed in normoinsulinemic subjects. Conclusion: The present study supports the notion that metformin may be considered as a prophylactic therapy lowering cardiovascular risk factors in hyperinsulinemic women with polycystic ovary syndrome.展开更多
文摘Objective: To test the hypothesis that statins improve hyperandrogenemia in women with polycystic ovary syndrome (PCOS).Design: Prospective, randomized trial.Setting: Academic medical center.Patient(s): Forty- eight women with PCOS.Intervention(s): Subjects were randomized to a statin group (simvastatin, 20 mg daily plus oral contraceptive pill [OCP]; n = 24) or an OCP group (OCP alone; n = 24).Main Outcome Measure(s): Serum T.Result(s): Baseline parameters of both groups were comparable.After 12 weeks of treatment, serum T levels declined by 41% in the statin group and by 14% in the OCP group.In the statin group, there was a greater decrease of LH (43% decrease vs.9% in the OCP group) and a greater decline of LH/FSH ratio (44% vs.12% ).In the statin group, total cholesterol declined by 10% and low- density lipoprotein (LDL) by 24% .In the OCP group, total cholesterol increased by 8% , and LDL was unchanged.Conclusion(s): This is the first study demonstrating that statin decreases T levels and normalizes gonadotropin levels in women with PCOS.Statin therapy might offer a novel approach, providing endocrine and cardiovascular benefits.
文摘Objective: Patients with polycystic ovary syndrome frequently suffer from hyperinsulinemia and adverse lipid profile. This study evaluated effects of metformin on lipid profile. Study design: Lipid profiles in hyperinsulinemic (n = 43) and normoinsulinemic (n = 45) subjects were compared. Hyperinsulinemic subjects were treated with metformin (500 mg po tid) and lipid profiles were reevaluated at 3 and 6 months of treatment. Results: The hyperinsulinemic group had significantly lower high-density lipoprotein (HDL) (by 11% ), higher total cholesterol to HDL ratio (by 23% ), and greater trigly cerides(by 57% ) than the normoinsulinemic group. Six- month metformin therapy in hyperinsulinemic women was associated with a significant decrease of insulin level (by 35% ), total cholesterol(by 11% ), low-density lipoprotein (LDL) (by 12% ), and triglycerides (by 33% ). Levels of lipids in hyperinsulinemic women after metformin therapy were comparable to levels observed in normoinsulinemic subjects. Conclusion: The present study supports the notion that metformin may be considered as a prophylactic therapy lowering cardiovascular risk factors in hyperinsulinemic women with polycystic ovary syndrome.
